Higher-dose oral semaglutide and other developments Novo Nordisk has developed higher-dose versions of oral semaglutide (25 mg and 50 mg) to target obesity and provide stronger blood sugar and weight loss effects
Reduction in symptoms after proximal selective vagotomy through increased dietary viscosity
It addresses the national discussion surrounding the GLP-1 medication shortage (e.g., Ozempic, Wegovy, Saxenda, Mounjaro, Zepbound) and alternative options like compounded formularies from 503A and 503B pharmacies.
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up
Rectal bleeding refers to any blood that passes from your anus, often during or after a bowel movement
Molecular Reality The hunger associated with cannabis is primarily driven by THCs interaction with the ghrelin hormone and the brains reward centers